The m<sup>6</sup>A modification of LINC01133 suppresses ER<sup>+</sup> breast cancer progression by modulating IGF2BP2 protein stability via a ubiquitination-dependent mechanism.

Front Oncol · 2025 · PMC12241053 · PMID 40641925

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

GSEA analysis revealed a notable trend of proliferation traits focused on the subset of ER + breast cancer exhibiting low levels of LINC01133 ( Figure 2a ) suggesting that LINC01133 might mediate the proliferation of ER + breast cancer.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

The m&lt;sup&gt;6&lt;/sup&gt;A modification of LINC01133 suppresses ER&lt;sup&gt;+&lt;/sup&gt; breast cancer progression by modulating IGF2BP2 protein stability via a ubiquitination-dependent mechanism.

The sentences

The m<sup>6</sup>A modification of LINC01133 suppresses ER<sup>+</sup> breast cancer progression by modulating IGF2BP2 protein stability via a ubiquitination-dependent mechanism.